What is Wedbush’s Estimate for Scholar Rock Q2 Earnings?

Scholar Rock Holding Co. (NASDAQ:SRRK) – Investment analysts at Wedbush lowered their Q2 2025 EPS estimates for shares of Scholar Rock in a research note issued on Wednesday, May 14th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.66) per share for the quarter, down from their previous forecast of ($0.61). Wedbush currently has a “Outperform” rating and a $50.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Scholar Rock’s Q3 2025 earnings at ($0.64) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.58) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($2.04) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at $0.49 EPS.

Scholar Rock Stock Performance

Scholar Rock stock opened at $30.55 on Monday. The firm has a 50 day simple moving average of $31.19 and a 200-day simple moving average of $35.96. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter last year, the firm earned ($0.59) EPS.

Hedge Funds Weigh In On Scholar Rock

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its position in shares of Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after purchasing an additional 379 shares during the period. GF Fund Management CO. LTD. boosted its position in shares of Scholar Rock by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company’s stock worth $77,000 after purchasing an additional 430 shares during the period. CWM LLC boosted its position in shares of Scholar Rock by 152.8% during the 1st quarter. CWM LLC now owns 996 shares of the company’s stock worth $32,000 after purchasing an additional 602 shares during the period. Amalgamated Bank boosted its position in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after purchasing an additional 620 shares during the period. Finally, Global Retirement Partners LLC boosted its position in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after purchasing an additional 766 shares during the period. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Insider Activity

In other news, insider Tracey Sacco sold 6,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now owns 71,750 shares of the company’s stock, valued at $2,373,490. This represents a 8.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Katie Peng sold 1,006 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $34.42, for a total transaction of $34,626.52. Following the completion of the sale, the director now directly owns 30,319 shares of the company’s stock, valued at approximately $1,043,579.98. This trade represents a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 255,231 shares of company stock valued at $9,220,236 in the last 90 days. Company insiders own 13.30% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.